A postdoc position in single-cell cancer omics bioinformatics is immediately available in the Foukakis Lab at Karolinska University Hospital, employed by Karolinska Institutet. Jointly with the Bienko-Crosetto Lab at Science for Life Laboratory.
The Foukakis Lab at Oncology/Pathology department, Karolinska Institutet focuses on clinical and translational studies on breast cancer. The aim is to better understand and predict an individual patient's unique drug sensitivity, improve breast cancer survival, and avoid treatment-related toxicity. Tumor tissue and liquid biopsies are available from patients enrolled in multiple academic prospective randomized trials, as well as from retrospective patient cohorts. A translational research platform has been set up using a multitude of pathology and genomic methods in a concerted effort to identify prognostic and predictive biomarkers. The group has a significant national and international presence and collaborations.
The Bienko-Crosetto Lab develops and leverages cutting-edge genomic technologies to study the interplay between 3D genome architecture and genome stability, with a strong focus on understanding how somatic copy number alterations and structural variants form and evolve in cancer cells and how they contribute to tumor progression.
As a single-cell cancer omics bioinformatician, you will lead the analysis and interpretation of scDNA-seq and single-cell multi-omic data that we are generating from patient samples collected in the frame of large multi-center clinical trials and develop/apply advanced computational approaches to model how tumors evolve under the continuous selective pressure of anti-cancer therapies.
You will work at the crossroad between the clinic and the research lab where sequencing data are being generated, embedded in a culturally diverse and dynamic research environment where you will work alongside clinicians and scientists from different fields and backgrounds.
Your main tasks will be:
To be eligible for employment as a postdoctoral researcher, a PhD or a foreign degree deemed to be equivalent to a Swedish PhD is required. This eligibility requirement must be fulfilled at the latest at the time of the employment decision. Completion of your doctoral degree within the last three years is considered an advantage. If there are special reasons, your degree may have been completed earlier.
Qualifications:
A creative and inspiring environment with wide-ranging expertise and interests. Karolinska Institutet is one of the world's leading medical universities. At Karolinska Institutet, we conduct successful medical research and hold the largest range of medical education in Sweden. At KI, you get to meet researchers working with a wide range of specialisms and methods, giving you ample opportunity to exchange knowledge and experience with the various scientific fields within medicine and health. It is the crossover collaborations, which have pushed KI to where it is today, at the forefront of global research. Several of the people you meet in healthcare are educated at KI. A close relationship with the health care providers is important for creating groundbreaking top quality education and research. Karolinska Institutet is also a state university, which entitles you to several benefits through our collective agreement.
Location: Solna, SciLifeLab.
Choose to work at KI – Ten reasons why
An employment application must contain the following documents in English or Swedish:
Welcome to apply at the latest 3th February.
The application is to be submitted through the Varbi recruitment system.
This position is for 2 years, with possibility of extension.
| Type of employment | Temporary position |
|---|---|
| Contract type | Full time |
| First day of employment | According to agreement |
| Salary | Monthly salary |
| Number of positions | 1 |
| Full-time equivalent | 100 % |
| City | Solna |
| County | Stockholms län |
| Country | Sweden |
| Reference number | STÖD 2-228/2026 |
| Contact |
|
| Union representative |
|
| Published | 20.Jan.2026 |
| Last application date | 03.Feb.2026 |